Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
Theodoros Karampitsakos, Ourania Papaioannou, Ilias Dimeas, Panagiota Tsiri, Vasilina Sotiropoulou, Ioannis Tomos, Ilias C. Papanikolaou, Matthaios Katsaras, Paraskevi Kirgou, Zoe Daniil, Konstantinos I. Gourgoulianis, Fotios Sampsonas, Effrosyni Manali, Spyridon Papiris, Demosthenes Bouros, Argyris Tzouvelekis
Source: ERJ Open Res, 8 (2) 00082-2022; 10.1183/23120541.00082-2022
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Theodoros Karampitsakos, Ourania Papaioannou, Ilias Dimeas, Panagiota Tsiri, Vasilina Sotiropoulou, Ioannis Tomos, Ilias C. Papanikolaou, Matthaios Katsaras, Paraskevi Kirgou, Zoe Daniil, Konstantinos I. Gourgoulianis, Fotios Sampsonas, Effrosyni Manali, Spyridon Papiris, Demosthenes Bouros, Argyris Tzouvelekis. Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis. ERJ Open Res, 8 (2) 00082-2022; 10.1183/23120541.00082-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|